An antiviral drug that was granted an emergency use authorization ... Molnupiravir, an antiviral developed by Merck & Co. works by causing mutations in the virus with the aim of weakening and ...

A new study released Monday said Merck's widely used antiviral Covid pill can cause mutations in the virus that occasionally ...

The pill, an antiviral drug called molnupiravir ... None died, officials with the pharmaceutical company Merck announced October 1 in a news release. Similar numbers of people taking the drug ...

Merck and Ridgeback Biotherapeutics announced on Friday early result that indicate their experimental oral antiviral drug molnupiravir might halve the risk of death or hospitalization from COVID-19.

On the efficacy issue, Merck told the meeting ... a temporary EUA until another oral antiviral candidate becomes available. The lack of data for the drug against the emerging Omicron variant ...

A panel of expert advisers to the U.S. Food and Drug Administration on Tuesday narrowly voted to recommend the agency authorize Merck & Co’s antiviral pill to treat COVID-19. If the FDA ...

At a glance Molnupiravir, originally developed to treat the flu, is an antiviral drug from global pharamaceutical Merck and Ridgeback Biotherapeutics Early results show it could halve the risk of ...

Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year.

If approved, it will be the first oral antiviral for COVID-19 ... birth defects in animal studies. Merck says however that its studies indicate that the drug does not affect mammalian DNA.

STAT's podcast The Readout Loud discusses Summit's cancer immunotherapy, the company's co-CEO, Moderna's spending cuts and ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Keytruda's dominance as a mainstay in cancer immunotherapy isn’t threatened by an experimental Chinese drug, a top Merck ...